000			01924cam^a2200409^a^4500
001			UDM01000144914
003			UDM
005			20210601015521.0
008			130319s2012^^^^dcua^^^^^b^^^^000^0^eng^^
020			_a0309218136 _q(pbk. : alk. paper)
020			_a0309218144 _q(PDF)
020			_a9780309218139 _q(pbk. : alk. paper)
020			_a9780309218146 _q(PDF)
040			_aDNLM/DLC _beng _cDLC _dYDX _dBTCTA _dNLM _dYDXCP _dBWX _dAAA _dCDX _dUN@
082	0	4	_a174.2951 _bE84 2012
245	1	0	_aEthical and scientific issues in studying the safety of approved drugs / _cCommittee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies.
264	3	1	_aWashington, D.C. : _bNational Academies Press, _cc2012.
300			_axvi, 275 páginas : _bilustraciones ; _c23 cm.
336			_atexto _btxt _2rdacontent
337			_ano mediado _bn _2rdamedia
338			_avolumen _bnc _2rdacarrier
504			_aIncluye bibliografía.
505	0		_aIncorporating benefit and risk assessment and benefit/risk management into food and drug administration decision-making -- Evidence and decision-making -- Selection and oversight of required postmarketing studies -- Synthesis.
650	1	4	_9335324 _aMedicamentos. _xPruebas _xAspectos morales y éticos _zEstados Unidos.
650	1	4	_9346898 _aPruebas clínicas. _xAspectos morales y éticos _zEstados Unidos.
710	2		_9148364 _aInstitute of Medicine (U.S.). _bCommittee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs.
942			_2ddc _cGEN
991			_aC0 _bUN@
991			_aCB _aPR13 _a000101358, Triana Contreras, Zeta Meva.
997			_aHZ _b00 _c20140722 _lUDM01 _h1028
998			_aBATCH-UPD _b00 _c20150424 _lUDM01 _h0723
999			_c132677 _d132677
900			_aADM
900			_aCC
900			_aCNT
900			_aCB